Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Metastatic Thyroid Cancer
NCT00176748Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2005
- Primary completion
- Aug 2006
- Countries
- 1
01
Overview
Phase 2, open-label trial of axitinib in thyroid cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2005; status: completed.
02
Drugs
axitinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00176748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176748.